中国卒中杂志 ›› 2024, Vol. 19 ›› Issue (6): 714-724.DOI: 10.3969/j.issn.1673-5765.2024.06.012
李之明,王孜杰,李琦
收稿日期:
2024-05-01
出版日期:
2024-06-20
发布日期:
2024-06-20
通讯作者:
李琦 qili_md@126.com
基金资助:
LI Zhiming, WANG Zijie, LI Qi
Received:
2024-05-01
Online:
2024-06-20
Published:
2024-06-20
Contact:
LI Qi, E-mail: qili_md@126.com
摘要: 脑出血(intracerebral hemorrhage,ICH)的急性期治疗一直是备受关注的话题。2024年来自多个国家的ICH专家在Stroke杂志上发布了急性自发性ICH的早期综合管理方案——Code ICH。该专家共识围绕ICH的急性期脑损伤机制、早期一体化诊治方案及未来研究方向提出了详细的推荐意见。本文将对该专家共识进行解读。
中图分类号:
李之明, 王孜杰, 李琦. 2024美国卒中学会Code ICH脑出血早期一体化诊治方案专家共识解读[J]. 中国卒中杂志, 2024, 19(6): 714-724.
LI Zhiming, WANG Zijie, LI Qi. Interpretation of the American Stroke Association Code ICH Expert Consensus Statement[J]. Chinese Journal of Stroke, 2024, 19(6): 714-724.
[1] GBD 2019 Stroke Collaborators. Global,regional,and national burden of stroke and its risk factors,1990—2019:a systematic analysis for the global burden of disease study 2019[J]. Lancet Neurol,2021,20(10):795-820. [2] VAN ASCH C J,LUITSE M J,RINKEL G J,et al. Incidence,case fatality,and functional outcome of intracerebral haemorrhage over time,according to age,sex,and ethnic origin:a systematic review and meta-analysis[J]. Lancet Neurol,2010,9(2):167-176. [3] DEMEL S L,STANTON R,AZIZ Y N,et al. Reflection on the past,present,and future of thrombolytic therapy for acute ischemic stroke[J/OL]. Neurology,2021,97(20 Suppl 2):S170–S177[2024-01-01]. https://doi.org/10.1212/WNL.0000000000012806. [4] LI Q,YAKHKIND A,ALEXANDROV A W,et al. Code ICH:a call to action[J]. Stroke,2024,55(2):494-505. [5] BROUWERS H B,CHANG Y C,FALCONE G J,et al. Predicting hematoma expansion after primary intracerebral hemorrhage[J]. JAMA Neurol,2014,71(2):158-164. [6] AL-SHAHI SALMAN R,FRANTZIAS J,LEE R J,et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage:a systematic review and meta-analysis of individual patient data[J]. Lancet Neurol,2018,17(10):885-894. [7] WANG X,ARIMA H,AL-SHAHI SALMAN R,et al. Clinical prediction algorithm(BRAIN)to determine risk of hematoma growth in acute intracerebral hemorrhage[J]. Stroke,2015,46(2):376-381. [8] YOGENDRAKUMAR V,MOORES M,SIKORA L,et al. Evaluating hematoma expansion scores in acute spontaneous intracerebral hemorrhage:a systematic scoping review[J]. Stroke,2020,51(4):1305-1308. [9] BOULOUIS G,MOROTTI A,BROUWERS H B,et al. Association between hypodensities detected by computed tomography and hematoma expansion in patients with intracerebral hemorrhage[J]. JAMA Neurol,2016,73(8):961-968. [10] OVESEN C,JAKOBSEN J C,GLUUD C,et al. Tranexamic acid for prevention of hematoma expansion in intracerebral hemorrhage patients with or without spot sign[J]. Stroke,2021,52(8):2629-2636. [11] GLADSTONE D J,AVIV R I,DEMCHUK A M,et al. Effect of recombinant activated coagulation factor Ⅶ on hemorrhage expansion among patients with spot sign-positive acute intracerebral hemorrhage:the SPOTLIGHT and STOP-IT randomized clinical trials[J]. JAMA Neurol,2019,76(12):1493-1501. [12] MOROTTI A,ARBA F,BOULOUIS G,et al. Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome:a meta-analysis[J]. Neurology,2020,95(14):632-643. [13] SPORNS P B,SCHWAKE M,KEMMLING A,et al. Comparison of spot sign,blend sign and black hole sign for outcome prediction in patients with intracerebral hemorrhage[J]. J Stroke,2017,19(3):333-339. [14] KEEP R F,HUA Y,XI G H. Intracerebral haemorrhage:mechanisms of injury and therapeutic targets[J]. Lancet Neurol,2012,11(8):720-731. [15] IRONSIDE N,CHEN C J,DING D,et al. Perihematomal edema after spontaneous intracerebral hemorrhage[J]. Stroke,2019,50(6):1626-1633. [16] WANG J. Preclinical and clinical research on inflammation after intracerebral hemorrhage[J]. Prog Neurobiol,2010,92(4):463-477. [17] CHEN Y H,CHEN S P,CHANG J B,et al. Perihematomal edema after intracerebral hemorrhage:an update on pathogenesis,risk factors,and therapeutic advances[J/OL]. Front Immunol,2021,12:740632[2024-01-01]. https://doi.org/10.3389/fimmu.2021.740632. [18] HUANG X Y,WANG D,MA Y Q,et al. Perihematomal edema-based CT-radiomics model to predict functional outcome in patients with intracerebral hemorrhage[J]. Diagn Interv Imaging,2023,104(9):391-400. [19] SUN W P,PAN W Q,KRANZ P G,et al. Predictors of late neurological deterioration after spontaneous intracerebral hemorrhage[J]. Neurocrit Care,2013,19(3):299-305. [20] ANDERSON C S,HEELEY E,HUANG Y N,et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage[J]. N Engl J Med,2013,368(25):2355-2365. [21] QURESHI A I,PALESCH Y Y,BARSAN W G,et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage[J]. N Engl J Med,2016,375(11):1033-1043. [22] TOYODA K,PALESCH Y Y,KOGA M,et al. Regional differences in the response to acute blood pressure lowering after cerebral hemorrhage[J/OL]. Neurology,2021,96(5):e740-e751[2024-01-01]. https://doi.org/10.1212/WNL.0000000000011229. [23] LEASURE A C,QURESHI A I,MURTHY S B,et al. Intensive blood pressure reduction and perihematomal edema expansion in deep intracerebral hemorrhage[J]. Stroke,2019,50(8):2016-2022. [24] LI Q,WARREN A D,QURESHI A I,et al. Ultra-early blood pressure reduction attenuates hematoma growth and improves outcome in intracerebral hemorrhage[J]. Ann Neurol,2020,88(2):388-395. [25] MOULLAALI T J,WANG X,MARTIN R H,et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage:a preplanned pooled analysis of individual participant data[J]. Lancet Neurol,2019,18(9):857-864. [26] MA L,HU X,SONG L L,et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial(INTERACT 3):an international,stepped wedge cluster randomised controlled trial[J]. Lancet,2023,402(10395):27-40. [27] RODRIGUEZ-LUNA D,PANCORBO O,LLULL L,et al. Effects of achieving rapid,intensive,and sustained blood pressure reduction in intracerebral hemorrhage expansion and functional outcome[J/OL]. Neurology,2024,102(9):e209244[2024-01-01]. https://doi.org/10.1212/WNL.0000000000209244. [28] LI G,LIN Y P,YANG J,et al. Intensive ambulance-delivered blood-pressure reduction in hyperacute stroke[J]. N Engl J Med,2024,390(20):1862-1872. [29] MAYER S A. Recombinant activated factor Ⅶ for acute intracerebral hemorrhage[J]. Stroke,2007,38(2 Suppl):763-767. [30] MAYER S A,DAVIS S M,SKOLNICK B E,et al. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor Ⅶ?[J]. Stroke,2009,40(3):833-840. [31] WILLIAMS-JOHNSON J A,MCDONALD A H,STRACHAN G G,et al. Effects of tranexamic acid on death,vascular occlusive events,and blood transfusion in trauma patients with significant haemorrhage(CRASH-2):a randomised,placebo-controlled trial[J]. West Indian Med J,2010,59(6):612-624. [32] CRASH-3 trial collaborators. Effects of tranexamic acid on death,disability,vascular occlusive events and other morbidities in patients with acute traumatic brain injury(CRASH-3):a randomised,placebo-controlled trial[J]. Lancet,2019,394(10210):1713-1723. [33] SPRIGG N,FLAHERTY K,APPLETON J P,et al. Tranexamic acid for hyperacute primary intracerebral haemorrhage(TICH-2):an international randomised,placebo-controlled,phase 3 superiority trial[J]. Lancet,2018,391(10135):2107-2115. [34] LIU J Y,NIE X M,GU H Q,et al. Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment(TRAIGE):a multicentre,randomised,placebo-controlled trial[J]. Stroke Vasc Neurol,2021,6(2):160-169. [35] MERETOJA A,YASSI N,WU T Y,et al. Tranexamic acid in patients with intracerebral haemorrhage(STOP-AUST):a multicentre,randomised,placebo-controlled,phase 2 trial[J]. Lancet Neurol,2020,19(12):980-987. [36] NIE X M,LIU J Y,LIU D C,et al. Haemostatic therapy in spontaneous intracerebral haemorrhage patients with high-risk of haematoma expansion by CT marker:a systematic review and meta-analysis of randomised trials[J]. Stroke Vasc Neurol,2021,6(2):170-179. [37] STEINER T,WEITZ J I,VELTKAMP R. Anticoagulant-associated intracranial hemorrhage in the era of reversal agents[J]. Stroke,2017,48(5):1432-1437. [38] STEINER T,POLI S,GRIEBE M,et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists(INCH):a randomised trial[J]. Lancet Neurol,2016,15(6):566-573. [39] KURAMATSU J B,GERNER S T,SCHELLINGER P D,et al. Anticoagulant reversal,blood pressure levels,and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage[J]. JAMA,2015,313(8):824-836. [40] GOLDSTEIN J N,THOMAS S H,FRONTIERO V,et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage[J]. Stroke,2006,37(1):151-155. [41] HUTTNER H B,SCHELLINGER P D,HARTMANN M,et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy:comparison of acute treatment strategies using vitamin K,fresh frozen plasma,and prothrombin complex concentrates[J]. Stroke,2006,37(6):1465-1470. [42] BISWAS S,BAHAR Y,BAHAR A R,et al. Present knowledge on direct oral anticoagulant and novel oral anti coagulants and their specific antidotes:a comprehensive review article[J/OL]. Curr Probl Cardiol,2023,48(2):101483[2024-01-01]. https://doi.org/10.1016/j.cpcardiol.2022.101483. [43] POLLACK C V,Jr,REILLY P A,VAN RYN J,et al. Idarucizumab for dabigatran reversal—full cohort analysis[J]. N Engl J Med,2017,377(5):431-441. [44] DEMCHUK A M,YUE P,ZOTOVA E,et al. Hemostatic efficacy and anti-FⅩa(factor Ⅹa)reversal with andexanet alfa in intracranial hemorrhage:ANNEXA-4 substudy[J]. Stroke,2021,52(6):2096-2105. [45] GHADIMI K,DOMBROWSKI K E,LEVY J H,et al. Andexanet alfa for the reversal of factor Ⅹa inhibitor related anticoagulation[J]. Expert Rev Hematol,2016,9(2):115-122. [46] SIEGAL D M,CURNUTTE J T,CONNOLLY S J,et al. Andexanet alfa for the reversal of factor Ⅹa inhibitor activity[J]. N Engl J Med,2015,373(25):2413-2424. [47] CONNOLLY S J,CROWTHER M,EIKELBOOM J W,et al. Full study report of andexanet alfa for bleeding associated with factor Ⅹa inhibitors[J]. N Engl J Med,2019,380(14):1326-1335. [48] GERNER S T,KURAMATSU J B,SEMBILL J A,et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage[J]. Ann Neurol,2018,83(1):186-196. [49] GÓMEZ-OUTES A,ALCUBILLA P,CALVO-ROJAS G,et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants[J]. J Am Coll Cardiol,2021,77(24):2987-3001. [50] COSTA O S,CONNOLLY S J,SHARMA M,et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban-or rivaroxaban-associated intracranial hemorrhage:a propensity score-overlap weighted analysis[J/OL]. Critical Care,2022,26(1):180[2024-01-01]. https://doi.org/10.1186/s13054-022-04043-8. [51] HUTTNER H B,GERNER S T,KURAMATSU J B,et al. Hematoma expansion and clinical outcomes in patients with factor-Ⅹa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care[J]. Stroke,2022,53(2):532-543. [52] CONNOLLY S J,SHARMA M,COHEN A T,et al. Andexanet for factor Ⅹa inhibitor-associated acute intracerebral hemorrhage[J]. N Engl J Med,2024,390(19):1745-1755. [53] SHETH K N,SOLOMON N,ALHANTI B,et al. Time to anticoagulation reversal and outcomes after intracerebral hemorrhage[J]. JAMA Neurol,2024,81(4):363-372. [54] GROSS B A,JANKOWITZ B T,FRIEDLANDER R M. Cerebral intraparenchymal hemorrhage:a review[J]. JAMA,2019,321(13):1295-1303. [55] MENDELOW A D,GREGSON B A,FERNANDES H M,et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage(STICH):a randomised trial[J]. Lancet,2005,365(9457):387-397. [56] MENDELOW A D,GREGSON B A,ROWAN E N,et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas(STICH Ⅱ):a randomised trial[J]. Lancet,2013,382(9890):397-408. [57] ZHOU X Y,CHEN J J,LI Q,et al. Minimally invasive surgery for spontaneous supratentorial intracerebral hemorrhage:a meta-analysis of randomized controlled trials[J]. Stroke,2012,43(11):2923-2930. [58] SONDAG L,SCHREUDER F H B M,BOOGAARTS H D,et al. Neurosurgical intervention for supratentorial intracerebral hemorrhage[J]. Ann Neurol,2020,88(2):239-250. [59] MORGENSTERN L B,FRANKOWSKI R F,SHEDDEN P,et al. Surgical treatment for intracerebral hemorrhage(STICH):a single-center,randomized clinical trial[J]. Neurology,1998,51(5):1359-1363. [60] HANLEY D F,THOMPSON R E,ROSENBLUM M,et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation(MISTIE Ⅲ):a randomised,controlled,open-label,blinded endpoint phase 3 trial[J]. Lancet,2019,393(10175):1021-1032. [61] PRADILLA G,RATCLIFF J J,HALL A J,et al. Trial of early minimally invasive removal of intracerebral hemorrhage[J]. N Engl J Med,2024,390(14):1277-1289. [62] GREGSON B A,BRODERICK J P,AUER L M,et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage[J]. Stroke,2012,43(6):1496-1504. [63] KELLNER C P,SONG R,ALI M,et al. Time to evacuation and functional outcome after minimally invasive endoscopic intracerebral hemorrhage evacuation[J/OL]. Stroke,2021,52(9):e536-e539[2024-01-01]. https://doi.org/10.1161/STROKEAHA.121.034392. [64] LJUNGQVIST O,SCOTT M,FEARON K C. Enhanced recovery after surgery:a review[J]. JAMA Surg,2017,152(3):292-298. [65] EVANS L,RHODES A,ALHAZZANI W,et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock 2021[J/OL]. Crit Care Med,2021,49(11):e1063-e1143[2024-01-01]. https://doi.org/10.1097/CCM.0000000000005337. [66] CARDO D,DENNEHY P H,HALVERSON P,et al. Moving toward elimination of healthcare-associated infections:a call to action[J]. Infect Control Hosp Epidemiol,2010,31(11):1101-1105. [67] MIDDLETON S,COUGHLAN K,MNATZAGANIAN G,et al. Mortality reduction for fever,hyperglycemia,and swallowing nurse-initiated stroke intervention:QASC trial(quality in acute stroke care)follow-up[J]. Stroke,2017,48(5):1331-1336. [68] PARRY-JONES A R,SAMMUT-POWELL C,PAROUTOGLOU K,et al. An intracerebral hemorrhage care bundle is associated with lower case fatality[J]. Ann Neurol,2019,86(4):495-503. |
[1] | 北京高血压防治协会, 中国卒中学会高血压预防与管理分会. 中国卒中患者高血压管理专家共识[J]. 中国卒中杂志, 2024, 19(6): 672-698. |
[2] | 伊珞, 姜英玉, 孟霞, 姜勇, 王拥军, 谷鸿秋. 轻型急性缺血性卒中患者院内神经功能恶化预测模型的开发与验证研究[J]. 中国卒中杂志, 2024, 19(5): 524-531. |
[3] | 李晨红, 姜晨黎, 王金慧, 黄晟. 脑出血患者微创颅内血肿清除术后肺部感染的影响因素分析及预测模型构建[J]. 中国卒中杂志, 2024, 19(5): 532-538. |
[4] | 丁则昱, 姬泽强, 吴建维, 康开江, 赵性泉. 幕上高血压性脑出血微创颅内血肿抽吸引流术后早期神经功能恶化危险因素分析[J]. 中国卒中杂志, 2024, 19(5): 545-551. |
[5] | 王伊龙. 脑小血管病的诊治现状及未来探索之路[J]. 中国卒中杂志, 2024, 19(4): 363-374. |
[6] | 陈玮琪, 徐佳洁, 陆瑶, 王玲, 曹瑾怡, 陈鸿宾, 郭蕾, 吕琰琛, 汤晗, 王赞, 徐非凡, 颜庭梦, 应云清, 仲伟逸, 周蓉, 陆正齐, 程忻, 王伊龙, 中国卒中学会脑小血管病分会. 中国脑小血管病的神经影像学诊断标准及名词标准化定义——来自中国卒中学会的专家共识[J]. 中国卒中杂志, 2024, 19(4): 376-404. |
[7] | 中国卒中学会医疗质量管理与促进分会, 《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》编写组. 中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明[J]. 中国卒中杂志, 2024, 19(4): 440-451. |
[8] | 刘昱君, 刘雷媛, 徐炳东, 韩建邦, 杨冰, 丁燕, 杨英, 孟珩, 张玉生. 伴皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病患者大脑中动脉闭塞血管内治疗1例并文献复习[J]. 中国卒中杂志, 2024, 19(4): 452-458. |
[9] | 郝曼均, 王利圆, 熊云云. 再灌注治疗的神经影像学评估[J]. 中国卒中杂志, 2024, 19(4): 459-467. |
[10] | 张莉, 刘志广, 傅新民, 张洋, 宗海亮. 院内大血管闭塞性卒中血管内治疗患者的临床特征及预后因素分析[J]. 中国卒中杂志, 2024, 19(3): 310-318. |
[11] | 闫喜格, 王国玲, 张博刚, 彭敏, 董中君, 申晓平, 陈秀晓, 贾倩, 董会格, 程莉. 急性颈动脉闭塞支架置入术后血管再闭塞补救性治疗方法——股-颈动脉转流术报道[J]. 中国卒中杂志, 2024, 19(3): 331-336. |
[12] | 于丹, 杨兰, 王垚. 基于Roy适应模式的程序式护理对卒中偏瘫患者自我管理和负面情绪的影响研究[J]. 中国卒中杂志, 2024, 19(3): 356-362. |
[13] | 许杰, 王拥军. 代谢性脑血管病的“多系统对话”与“多学科共管”[J]. 中国卒中杂志, 2024, 19(2): 125-129. |
[14] | 梁小雪, 郭黎. 肥胖相关慢性炎症与代谢性脑血管病[J]. 中国卒中杂志, 2024, 19(2): 138-144. |
[15] | 钱金平, 吴丹, 郭小玲. 脑心健康管理师核心胜任力评价指标体系的构建研究[J]. 中国卒中杂志, 2024, 19(2): 181-189. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||